Danicopan Early Access Program

Exclusion Criteria

• • Participants who are nursing or pregnant (or women who are planning to become
• pregnant during treatment with danicopan).
• • Laboratory abnormalities at screening, as follows:
• • Alanine aminotransferase (ALT) > 2 × upper limit of normal (ULN)
• • Direct bilirubin > 2 × ULN, with the exception of:
• o participants with increased bilirubin due to EVH in the opinion of the
• Treating Physician or
• o participants with documented Gilbert’s syndrome
• • Active bacterial or viral infection, a body temperature > 38°C on 2 consecutive daily
• measures, evidence of other infection, or history of any febrile illness within 14 days prior
• to initiating danicopan treatment.